Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Health Claims Review Limits Language, Raises Costs For Firms

This article was originally published in The Tan Sheet

Executive Summary

Nutritional supplement firms in Europe face escalating costs for differentiating their product claims under a master list of general health claims the European Food Safety Authority is compiling

You may also be interested in...



Functional Food Ingredients Emerging To Compete With OTC Drugs

Some ailments “are going to be more pervasive” with people living longer and consumers will look more toward functional foods to address them, says Mintel analyst Nirvana Chapman. The shift partly reflects rising health care costs and consumers’ efforts to save money through preventive care and less costly treatments.

Functional Food Ingredients Emerging To Compete With OTC Drugs

Some ailments “are going to be more pervasive” with people living longer and consumers will look more toward functional foods to address them, says Mintel analyst Nirvana Chapman. The shift partly reflects rising health care costs and consumers’ efforts to save money through preventive care and less costly treatments.

European Nutrition Groups Challenge EFSA Health Claims Policy

European industry trade associations file a lawsuit to block the implementation of what they call EFSA’s restrictive list of permitted health claims. The groups demand the annulment of the general function claim list and ask the EC to “correct the flaws in its approach.”

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel